Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MagicTime Medicine is a Yale University spinout biotechnology company pioneering a new paradigm of immune gene therapy. Founded by Dr. Sidi Chen, the company utilizes its proprietary MAEGI (Multiplexed Activation of Endogenous Genes for Immunotherapy) platform to directly activate multiple endogenous genes to stimulate a robust immune response against tumors. Unlike traditional immunotherapies, MagicTime's approach leverages both viral and non-viral delivery systems to modulate the immune system and develop next-generation vaccines for cancer and other complex diseases. The company is currently in the preclinical stage and has received significant support from the Blavatnik Fund for Innovation at Yale.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MagicTime Medicine.